报价延迟最少15分钟:2025/09/15 09:00 EDT
盘前时段
|
||||
|
1.06 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
--
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.04/0.17
|
|
企业价值
18.38M
|
| 资产负债 |
|
每股账面净值
2.36
|
| 现金流量 |
|
现金流量率
0.08
|
| 损益表 |
|
收益
1.76M
|
|
每股收益
6.03
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/15 09:00 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories. |
